Evotec 566480, wohin geht die Reise??? (Seite 6555)

[akfan]

Evotec acquires 70% controlling majority stake of Research Support International Private Limited ('RSIPL'), India,

Evotec übernimmt die restlichen 30 % an RSIPL (Indien)für 2,3 Mio. USD und ist nun alleiniger Eigentümer. Cash ist ja reichlich geflossen in Q3.

Strategisch richtiger Schritt, Evotec ist nun unabhängig von den Minderheitsbeteiligten in Indien. Könnte mir vorstellen, dass nun geplant wird, bei der indischen Geschäftseinheit kostengünstige Kapazitäten auszubauen.

[Hoffnungstraeger]

Antwort auf Beitrag Nr.: 42.146.429 von Finee am 28.09.11 17:41:32

na freunde,wie weit fallen wir noch1,4

[Finee]

Top Story:
6. August 2009

[Finee]

Immer nur englisch:

TOP STORY
Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL

Evotec acquires 70% controlling majority stake of Research Support International Private Limited ('RSIPL'), India, for EUR 2.8 million in cash
Expansion of capacity accelerates Evotec's strategy to become the global, premier provider of drug discovery and early development alliances
Evotec maintains liquidity guidance of more than EUR 65 million by year-end 2009
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) and DIL Limited, India, announced today the signing of a definitive agreement to acquire a 70% controlling majority stake of the drug discovery service company RSIPL for EUR 2.8 million in cash, a portion of which includes a potential earn-out.

This transaction represents an important capacity expansion for Evotec. It adds a complementary drug discovery operation and capability in the field of science-driven chemistry work in a cost-effective location to Evotec's already world-leading discovery platform and efficiently increases its ability to deliver high quality, know-how driven drug discovery and development services to its partners on a global scale.

"It is important to strengthen the strategic position of Evotec's Discovery Alliance Business with the best technology offering and the most efficient global reach and cost strategy. This is a very important step in our strategy "Evotec 2012 - Action Plan to Focus and Grow", said Werner Lanthaler, CEO of Evotec.

"With this acquisition we reinforce our strategic commitment to deliver the highest value, know-how driven services and build the strongest innovation alliances with our customers. Evotec continues to accelerate its strong track record in Innovation and Process Excellence with the best scientists in the industry," commented Mario Polywka, COO of Evotec.

"We are happy to undertake this strategic partnership with Evotec in the development of RSIPL and believe in the growth strategy of the Discovery Alliance Business of Evotec. The partnership with Evotec would lend substantially to the growth of RSIPL and we look forward to a successful association with them", commented Krishna Datla, Managing Director of DIL.

RSIPL, located in Thane near Mumbai, was founded in 2004 and currently employs approximately 160 employees. The company is a 100% subsidiary of DIL, a publicly listed company on the Bombay Stock Exchange. Following the transaction, RSIPL will be integrated, as Evotec India, into the value chain of Evotec's operations in Hamburg (Germany) and Abingdon (UK). The deal is expected to close latest in early September, 2009. Evotec has a call option to purchase the remaining 30% from DIL in the future in the event of a change-of-control.

Despite this and the recent acquisition of the zebrafish technology platform, Evotec maintains it guidance to have more than EUR 65 million in liquid funds available by the end of 2009.

About RSIPL
Incorporated in 2004, Research Support International Private Limited ('RSIPL') is a 100% subsidiary of DIL Ltd (formerly Duphar-Interfran Ltd.) providing Drug Discovery & Development services. RSIPL is a vibrant organization committed to provide a strong & reliable fundamental research platform to enable its customers to accelerate their drug discovery programs efficiently and cost effectively.
RSIPL's uses its world class Infrastructure and Facilities to synthesis virtually all types of organic compounds from milligram to kilogram scale.
RSIPL was conferred the "Partner of Choice in Contract Research - Chemistry Based Services" award for the year 2007 by Frost & Sullivan in recognition of its experience in offering a organic synthesis services to pharmaceutical and biotech customers worldwide.

About DIL
Founded in 1951, DIL has built successful partnerships with global players in the Life Sciences Industry.
Apart from RSIPL, DIL's ventures in the Pharmaceutical Industry include commercial scale manufacturing and marketing of bulk drugs, intermediates, formulations & enzymes. DIL also engages in proprietary Research & Development of its own molecules, formulation, enzyme and enzyme application.

Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: [phone], [e-mail]

[Marmolata]

!

Dieser Beitrag wurde von ArbiMod moderiert. Grund: Thema \"Boardmails\" gehört nicht in die Diskussion

[Finee]

Evotec AG (EVT) agreed to buy the 30 percent stake it doesn’t own in its joint venture in India with DIL Ltd. (DILL), the Indian company said today in a regulatory filing.
The purchase price is 112.9 million rupees ($2.3 million), according to the filing.
To contact the reporter on this story: Allison Connolly in Frankfurt at [e-mail]
To contact the editor responsible for this story: Phil Serafino at [e-mail]

[Finee]

28th-Sep-2011 19:25Source: BSE
DIL - Outcome of Board Meeting
Dil Ltd has informed BSE that the Board of Directors of the Company at its meeting held on September 28, 2011, has Considered and approved the following:

1. The Board of Directors of DIL has approved the execution of a Share Purchase Agreement (Agreement) primarily between DIL Ltd (Transferor) and Evotec AG (Transferee), concerning transfer of 1,09,26,000 fully paid equity shares (face value of Rs. 2/- per share) i.e. 30% of the paid up equity share capital of Evotec (India) Pvt. Ltd. (EIPL), currently an associate company of DIL, for a total consideration of Rs. 11,29,33,210 (Rupees Eleven crores Twenty nine lakhs Thirty three thousand Two hundred ten only). The above transaction is anticipated to close on October 04, 2011.

Post transfer of shares in EIPL, DIL will not hold any equity shares in the paid up equity share capital in EIPL.

2. The Board of Directors of DIL has also approved and authorized filing of requisite application(s) with statutory authorities, including Thane Municipal Corporation, for seeking permission to redevelop part of its Thane property situated at 'DIL' complex, Ghodbunder Road, Majiwada, Thane (West) —400610.
http://www.moneycontrol.com/stocks/stock_market/corp_notices…

[Marmolata]

Zitat von hubidoc: HERRLICH!!!!!!!!!!!

EVOS Butter und Brotgeschäft läuft wie geschmiert,das ich das noch erleben darf,
das sie Gewinne machen

einfach klasse

das andere ist fantasie ,und wohin die uns führen kann.....

prost den langzeitanlegern,das wird noch ne richtig große nummer,

übernahme sehe ich im moment nicht bei der mk,
bin froh immer wieder zugekauft habe,als alles düster war

Hi, hubidoc, schön, das Du wieder hier aufgetaucht bist, ich bin noch voll dabei und habe immer wieder nachgekauft, genau wie Du. Schreib mir mal wieder per BM, bin auch an Wissenschaftlichem auch außer der Reihe interessiert. Der jetztige Kursverlauf könnte auf baldige News schließen, denke ich, da alles auf der Lauer liegt, obwohl die Zahlen noch weit entfernt sind. (3. Q 10 Nov.)

Wie siehst Du es?

[hubidoc]

HERRLICH!!!!!!!!!!!

EVOS Butter und Brotgeschäft läuft wie geschmiert,das ich das noch erleben darf,
das sie Gewinne machen

einfach klasse

das andere ist fantasie ,und wohin die uns führen kann.....

prost den langzeitanlegern,das wird noch ne richtig große nummer,

übernahme sehe ich im moment nicht bei der mk,
bin froh immer wieder zugekauft habe,als alles düster war

[akfan]

Phase I neuropatische Schmerzen mit Boehringer ist abgeschlossen!


Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

This study has been completed.

First Received on April 19, 2011. Last Updated on September 21, 2011